M
Mohammed M. Alanazi
Researcher at King Saud University
Publications - 74
Citations - 1199
Mohammed M. Alanazi is an academic researcher from King Saud University. The author has contributed to research in topics: Docking (molecular) & Population. The author has an hindex of 13, co-authored 67 publications receiving 592 citations. Previous affiliations of Mohammed M. Alanazi include Nova Southeastern University.
Papers
More filters
Journal ArticleDOI
MEG3: an Oncogenic Long Non-coding RNA in Different Cancers.
TL;DR: Biological function of MEG3 to repress tumor through regulating the major tumor suppressor genes p53 and Rb, inhibiting angiogenesis-related factor, or controlling miRNAs is highlighted.
Journal ArticleDOI
Whole Cigarette Smoke Increased the Expression of TLRs, HBDs, and Proinflammory Cytokines by Human Gingival Epithelial Cells through Different Signaling Pathways
TL;DR: By promoting TLR, HBDs, and proinflammatory cytokine expression and production, cigarette smoke may contribute to innate immunity dysregulation, which may have a negative effect on human health.
Journal ArticleDOI
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Mohammed M. Alanazi,Ibrahim H. Eissa,Nawaf A. Alsaif,Ahmad J. Obaidullah,Wael A. Alanazi,Abdullah F. Alasmari,Hussam Albassam,Hazem Elkady,Alaa Elwan +8 more
TL;DR: In this article, inhibition of VEGFR-2 activity proved effective suppression of tumour propagation, which plays a critical role in cancer angiogenesis, and showed that VEGF-2 plays an important role in the development of cancer angiomelioration.
Journal ArticleDOI
New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Nawaf A. Alsaif,Mohammed A. Dahab,Mohammed M. Alanazi,Ahmad J. Obaidullah,Abdulrahman A. Almehizia,Manal M. Alanazi,Saleh Aldawas,Hazem A. Mahdy,Hazem Elkady +8 more
TL;DR: In this article, a series of [1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one and [1 2,4], triazolo [4, 3-a]-quinoxaline derivatives have been designed, synthesized, and biologically assessed for their anti-proliferative activities against two selected tumor cell lines MCF-7 and HepG2.
Journal ArticleDOI
A potential anticancer dihydropyrimidine derivative and its protein binding mechanism by multispectroscopic, molecular docking and molecular dynamic simulation along with its in-silico toxicity and metabolic profile.
Tanveer A. Wani,Nawaf A. Alsaif,Mohammed M. Alanazi,Ahmed H. Bakheit,Seema Zargar,Mashooq A. Bhat +5 more
TL;DR: In this article, a newly synthesized and patented anticancer dihydropyrimidine derivative; 4-(4-ethoxyphenyl)-5-(3,4,5- trimethoxybenzoyl)-3, 4-dihydropyrimidin-2(1H)-one (DHP) was evaluated for its binding to HSA.